期刊文献+

慢性药物性肝损伤33例临床特点分析 被引量:11

Clinical characteristics of 33 patients with drug induced chronic liver injury
原文传递
导出
摘要 目的了解慢性药物性肝损伤临床特点。方法回顾性分析2001年4月至2010年8月北京大学第一医院感染疾病科随访的33例慢性药物性肝损伤患者临床特点。结果 33例患者平均年龄(40±15)岁;女性22例(66.7%)。27例(82%)起病时肝损伤为肝细胞型,淤胆型和混合型少见,分别为2例(6%)和4例(12%)。27例肝细胞型肝损伤中,23例(85.2%)起病时类似急性黄疸型肝炎;14例(51.8%)病理显示慢性肝炎。所有患者,12例(36.4%)治愈;3例(9%)发展为肝硬化,平均病程32个月;2例(6%)死亡。涉及药物,中药所占比例最高42.9%,依次为抗生素31%,心血管药物11.9%。结论慢性药物性肝损伤女性多见,多数有类似急性黄疸型肝炎的起病过程。部分可以治愈,少部分可发展为肝硬化。中药是引起慢性药物肝损伤的重要原因之一。 Objective To investigate clinical characteristics of drug induced chronic liver injury (DICLI). Methods A retrospective study was conducted to analyze medical records of 33 DICLI patients who had been treated in our institute from April 2001 to August 2010. DICLI was defined as a persistent biochemical abnormality for more than 6 months after drug withdrawal. Results The mean age of the 33 patients was (40 + 15 ) years. There were 22 females (66. 7 % ). Of the 33 patients at the onset of liver damage,27 (82%) showed hepatocellular type of injury ,2 (6%)showed eholestatic type and 4 ( 12% ) showed mixed type. Among the 27 cases of hepatoeellular injury,23 (85.2%) resembled acute icteric hepatitis at the onset of liver damage,and 14 (51.8%) showed pathological changes of chronic hepatitis. Of the 33 patients, 12 ( 36. 4% ) were eventually healed, 3 (9%) developed cirrhosis after a mean disease course of 32 months,and 2 (6%) died. Herbal medications contributed to 42. 9% of the DICLI cases,followed by antibiotics (31%) and cardiovascular drugs ( 11.9% ). Conclusion DICI is more common in females than in males. Most DICLI patients have a similar onset of acute icteric hepatitis. Some DICLI patients can be cured while some may progress to cirrhosis. Herbal medications may be a major cause of DICLI.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2011年第12期941-943,共3页 Chinese Journal of Practical Internal Medicine
关键词 药物 慢性肝损伤 drugs chronic liver injury
  • 相关文献

参考文献7

  • 1Andrade RJ ,Lucena MI ,Kaplowitz N ,et al. Outcome of Acute Idiosyn- cratic Drug-Induced Liver Injury:Long-Term Follow-up in a Hepato- toxicity Registry[J~. Hepatology,2006,44(6) :1581 - 1588.
  • 2Bjornsson E, Kalaitzakis E, Av Klinteberg V, et al. Long-term fol- low-up of patients with mild to moderate drug-induced liver injury [ J ]. Aliment Pharmacol Ther,2007,26 (1) :79 -85.
  • 3Danan G, Benichou C. Causality assessment of adverse reactions to drugs I. A novel method based on the conclusions of interuational consensus meetings:application to drug-induced liver injuries[ J]. J Clin Epidemiol, 1993,46 ( 11 ) : 1323 - 1330.
  • 4Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting [ J ]. J Hepatol, 1990, 11 ( 2 ) : 272 - 276.
  • 5Kaplowitz N. Drug-induced liver disorders: Implications for drug development and regulation [ J ]. Drug Saf, 2001,24 ( 7 ) : 483 - 490.
  • 6Andrade RJ,Lueena MI, Fernandez MC, et al. Drug-indueed liver injury:an analysis of 461 incidences submitted to the Spanish reg- istry over a 10-year period [ J]. Gastroenterology,2005,129 (2) : 512 -521.
  • 7李晨,万谟彬.慢性乙型病毒性肝炎抗病毒治疗指南的比较和解读[J].中国实用内科杂志,2010,30(12):1085-1087. 被引量:9

二级参考文献10

  • 1万谟彬.治疗慢性乙型肝炎核苷(酸)类似物的药物选择[J].中国感染与化疗杂志,2007,7(1):68-72. 被引量:11
  • 2Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases : prospective cohort study[ J]. BMJ,2004,328:983.
  • 3European Association For The Study Of The Liver. EASL Clinical Practice Guidelines:management of chronic hepatitis B [ J ]. J Hep- atol,2009 ,50 :227 - 242.
  • 4Yao GB. Enteeavir is a potent anti-HBV drug superior to lamivudi- ne:experience from clinical trials in China[ J ]. J Antimicrob Che- mother,2007,60:201 - 205.
  • 5van Bommel F,de Man RA, Stein K, et al. A multicenter analysis of antiviral response after one year of tenofovir mono-therapy in HBVmonoinfected patients with prior nucleos(t) ide analog experi- ence [ J ]. J Hepatol,2008,48 : S32.
  • 6Keeffe EB,Zeuzem, Koff RS, et al. Report of an international work- shop : roadmap for management of patients receiving oral therapy for chronic hepatitis B [ J ]. Clin Gastroenterol Hepatol,2007 ,5 :890 - 897.
  • 72005年全国人群乙肝血清流行病学调查结果.卫生部疾病控制专题新闻发布会:http://www.gov.cn/xwfb/2008-04/21/content_950425.htm.
  • 8Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [ J ]. JAMA,2006 ,295 :65 - 73.
  • 9万谟彬.慢性乙型肝炎抗病毒治疗的药物选择[J].内科理论与实践,2009,4(2):85-88. 被引量:4
  • 10慢性乙型肝炎抗病毒治疗专家共识[J].中华实验和临床感染病杂志(电子版),2010,4(1):49-53. 被引量:68

共引文献8

同被引文献135

引证文献11

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部